All together, our results show that genome wide patterns of alteration differ between EGFR and KRAS mutated lung ADC, describe two models of oncogenic cooperation involving either EGFR mutation and CDKN2A deletion or cyclin amplification and TP53 inactivating mutations and identified new chromosome regions at 7p and 14q associated to EGFR mutations in lung cancer.
Other purely growth-promoting mutations, in either E2F/DP or Cyclin E, could not substitute for RasACT in scrib- cells nor could insults to MAPK pathway effectors, such as PI3 kinase, Ral, Rho, Rac or Cdc 42, however, activated Notch exerted a RasACT-like hyperplastic effect in scrib- cells [ 3].
In addition, mutations in either the kinase or cyclin sub-unit might affect localization and interaction with the associating partner (e.g. deletion of the B-type cyclin, cdc13 in S. pombe prevents the nuclear accumulation of the kinase subunit, Cdc2p) [28].
We found that mutation of these sites to alanine abolished Pin1 Rb interaction, whereas the expression of Cyclin A, Cyclin D1 or Cyclin E enhances Pin1 Rb binding.
Second, they show that mutation of cyclin T1 surface residues that contact AFF4 impairs binding.
The gene most upregulated by hypoxia and VHL mutation was cyclin D1.
We also identified an intermediate mutation in Cyclin D (CCND3) that could be targeted with several drugs that are currently in clinical trials (LY2835219, LEE011,BAY1000394), or Palbociclib.
We also found an intermediate mutation in cyclin D3 (CCND3), which interacts with RBL2, and a mutation in NOTCH1 involved in regulating differentiation.
The aim of this study was to investigate the clinical relevance of BRAF V600E mutation status, cyclin D1 expression and MSI status of primary tumours of patients with mCRC treated with front-line 5FU-based chemotherapy.
Intestines from Apc −/+ mice were analyzed by immunohistochemistry for the expression and distribution of three central components of the Cdk4 signaling pathway downstream of Apc mutation, Cdk4, cyclin D1, and pRb.
